Characteristics of deceased patients
| Characteristic . | Patient no. . | |||
|---|---|---|---|---|
| 3 . | 12 . | 14 . | 15 . | |
| Time from diagnosis to entry, mo | 0.5 | 8.1 | 55 | 9.5 |
| Age, y | 59 | 67 | 70 | 44 |
| Time from study entry to death, mo | 0.4 | 3.2 | 1.2 | 0.7 |
| Previous treatment | None | MP | MP, alemtuzemab | Tandem SCT |
| No. of organs involved | 2 | 1 | 2 | 3 |
| History of syncope | No | No | No | Yes |
| NYHA class | 3 | 2 | 1 | 2 |
| Seated blood pressure | 90/60 | 85/40 | 130/78 | 70/50 |
| Creatinine level, mg/dL | 1.2 | 2.5 | 1.0 | 1.4 |
| NT-proBNP level, ng/L | 6178 | 5672 | 345 | 42 844 |
| Troponin T level, μg/L | < 0.01 | 0.1 | < 0.01 | 0.6 |
| Cardiac biomarker stage | 2 | 3 | 2 | 3 |
| Interventricular septum, mm | 12 | 17 | 24 | 14 |
| Left ventricular ejection fraction, % | 55 | 61 | 53 | 22 |
| Characteristic . | Patient no. . | |||
|---|---|---|---|---|
| 3 . | 12 . | 14 . | 15 . | |
| Time from diagnosis to entry, mo | 0.5 | 8.1 | 55 | 9.5 |
| Age, y | 59 | 67 | 70 | 44 |
| Time from study entry to death, mo | 0.4 | 3.2 | 1.2 | 0.7 |
| Previous treatment | None | MP | MP, alemtuzemab | Tandem SCT |
| No. of organs involved | 2 | 1 | 2 | 3 |
| History of syncope | No | No | No | Yes |
| NYHA class | 3 | 2 | 1 | 2 |
| Seated blood pressure | 90/60 | 85/40 | 130/78 | 70/50 |
| Creatinine level, mg/dL | 1.2 | 2.5 | 1.0 | 1.4 |
| NT-proBNP level, ng/L | 6178 | 5672 | 345 | 42 844 |
| Troponin T level, μg/L | < 0.01 | 0.1 | < 0.01 | 0.6 |
| Cardiac biomarker stage | 2 | 3 | 2 | 3 |
| Interventricular septum, mm | 12 | 17 | 24 | 14 |
| Left ventricular ejection fraction, % | 55 | 61 | 53 | 22 |
Data are from time of study entry, unless otherwise indicated. All patients had cardiac involvement.
To convert creatinine level from milligrams per deciliter to micromoles per liter, multiply milligrams per deciliter by 88.4.
NT-proBNP indicates N-terminal pro-brain natriuretic peptide; MP, melphalan and prednisone; and SCT, stem cell transplantation.